For patients with small volume Gleason 7 tumors, genomic testing can help determine if the tumor is minimally aggressive and behaves more like a Gleason 6.

“if I have a patient who has a single biopsy core that has 10% prostate cancer that's 1.5 mm of prostate cancer and that that and he has 5% pattern for think about how little disease that is that has potential issues with lethality what I do with that sample is I send it off to vericite for decipher testing and I have them look because about 70% of the time those small Volume glein 7 tumors genomically are minimally aggressive but I want to I want to delineate that so they behave more like the sixes they behave like a six”